NEJM Editors Call for Removal of Sibutramine from U.S. Market

Earlier this year, following the discovery of signals of potential danger in a large clinical trial, the weight loss drug sibutramine (Meridia) was wi...

To continue reading, please log in to the right or request an invitation.